KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to -$10.8 million.

  • Jazz Pharmaceuticals' Cash from Financing Activities fell 104.39% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$957.1 million, marking a year-over-year decrease of 1238.31%. This contributed to the annual value of $20.5 million for FY2024, which is 106.72% up from last year.
  • Jazz Pharmaceuticals' Cash from Financing Activities amounted to -$10.8 million in Q3 2025, which was up 91.30% from -$124.5 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Cash from Financing Activities ranged from a high of $4.7 billion in Q2 2021 and a low of -$813.5 million during Q1 2025.
  • For the 3-year period, Jazz Pharmaceuticals' Cash from Financing Activities averaged around -$112.1 million, with its median value being -$78.5 million (2023).
  • Data for Jazz Pharmaceuticals' Cash from Financing Activities shows a peak YoY increase of 625.88% (in 2021) and a maximum YoY decrease of 1,953.24% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Cash from Financing Activities stood at -$246.6 million in 2021, then soared by 107.95% to $19.6 million in 2022, then tumbled by 611.87% to -$100.3 million in 2023, then surged by 91.75% to -$8.3 million in 2024, then tumbled by 104.39% to -$10.8 million in 2025.
  • Its Cash from Financing Activities stands at -$10.8 million for Q3 2025, versus -$124.5 million for Q2 2025 and -$813.5 million for Q1 2025.